{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:25:16Z","timestamp":1793305516623,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["Z2021008"],"award-info":[{"award-number":["Z2021008"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["YSZD202401"],"award-info":[{"award-number":["YSZD202401"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.drup.2025.101300","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:37:40Z","timestamp":1757349460000},"page":"101300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2902-1813","authenticated-orcid":false,"given":"Caolu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruofan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoren","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.drup.2025.101300_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.drup.2025.101300_bib2","doi-asserted-by":"crossref","first-page":"xiii","DOI":"10.1016\/j.thorsurg.2022.08.001","article-title":"Overview of the management of esophageal cancer","volume":"32","author":"Yeung","year":"2022","journal-title":"Thorac. Surg. Clin."},{"issue":"5","key":"10.1016\/j.drup.2025.101300_bib3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal Squamous-Cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10302","key":"10.1016\/j.drup.2025.101300_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet (Lond. Engl. )"},{"issue":"9","key":"10.1016\/j.drup.2025.101300_bib5","first-page":"1137","article-title":"Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st trial","volume":"5","author":"He","year":"2024","journal-title":"Med (N. Y. NY)"},{"issue":"1","key":"10.1016\/j.drup.2025.101300_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.apsb.2021.05.003","article-title":"GSH-sensitive polymeric prodrug: synthesis and loading with photosensitizers as nanoscale chemo-photodynamic anti-cancer nanomedicine","volume":"12","author":"Luo","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2025.101300_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121061","article-title":"Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models","volume":"277","author":"Tan","year":"2021","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.drup.2025.101300_bib8","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.7150\/thno.57828","article-title":"Recent progress in nanomedicine for enhanced cancer chemotherapy","volume":"11","author":"Wei","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2025.101300_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.actbio.2020.12.009","article-title":"Clinical applications of nanomedicines in lung cancer treatment","volume":"121","author":"Norouzi","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.drup.2025.101300_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121961","article-title":"Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis","volume":"623","author":"Lu","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.drup.2025.101300_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.annonc.2020.10.479","article-title":"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial","volume":"32","author":"Shi","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2025.101300_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.drup.2025.101300_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2025.101300_bib14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/cas.15584","article-title":"AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma","volume":"114","author":"Zheng","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.drup.2025.101300_bib15","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer Immunotherapy-Blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.drup.2025.101300_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/BS9.0000000000000149","article-title":"PD-L1: expression regulation","volume":"5","author":"Zhou","year":"2023","journal-title":"Blood Sci."},{"issue":"7","key":"10.1016\/j.drup.2025.101300_bib17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.drup.2025.101300_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000437","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study","volume":"8","author":"Shen","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.drup.2025.101300_bib19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17512433.2023.2274544","article-title":"Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials","volume":"16","author":"Abushanab","year":"2023","journal-title":"Expert Rev. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.drup.2025.101300_bib20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1245\/s10434-023-14534-9","article-title":"A comparison of clinicopathologic outcomes and patterns of lymphatic spread across neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma","volume":"31","author":"Tian","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.drup.2025.101300_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1372272","article-title":"Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations","volume":"15","author":"Groen-van Schooten","year":"2024","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.drup.2025.101300_bib22","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1038\/s41467-020-20019-0","article-title":"Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment","volume":"11","author":"Zheng","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.drup.2025.101300_bib23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41416-022-02099-5","article-title":"Lactate dehydrogenase: relationship with the diagnostic GLIM criterion for cachexia in patients with advanced cancer","volume":"128","author":"McGovern","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.drup.2025.101300_bib24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/jcsm.12778","article-title":"Associations of low hand grip strength with 1 year mortality of cancer cachexia: a multicentre observational study","volume":"12","author":"Song","year":"2021","journal-title":"J. Cachex.. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.drup.2025.101300_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","article-title":"Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial","volume":"9","author":"Liu","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.drup.2025.101300_bib26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","article-title":"Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in wuhan, China: a multicentre, retrospective, cohort study","volume":"21","author":"Tian","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.drup.2025.101300_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"Journal National Comprehensive Cancer Network JNCCN"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:20:15Z","timestamp":1772886015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764625001037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"alternative-id":["S1368764625001037"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2025.101300","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2025.101300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101300"}}